Exosome therapy is marketed for skin rejuvenation and anti-aging, but the human evidence for those uses is still very limited. Exosomes are small vesicles released by cells. Many exosome products are made from the culture fluid of stem cells, not from the exosomes alone. In 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) and the Japanese Society for Regenerative Medicine (JSRM) both said that exosome-based treatments are not yet supported by established evidence. This page explains what exosomes are, what Japanese authorities have said, and what the research shows.
What exosomes are
Cells release membrane-enclosed particles of different sizes. Exosomes are one of the smaller types, typically in the nanometer range. They carry proteins, nucleic acids such as microRNA, and lipids, and scientists think they help cells communicate.
Regenerative medicine researchers became interested in exosomes because some effects attributed to stem cells may come from the substances those cells release. That led to the question of whether exosomes alone, without the cells, could provide similar benefit.
Most exosome products sold to patients are made from the culture fluid of stem cells, such as fat-derived, umbilical cord-derived or iPS cell-derived cultures. Some clinics use the culture fluid directly. These materials are often described interchangeably, but their composition and purity can differ a great deal.
What the research shows
Laboratory and animal studies. Exosomes have been studied in wound healing, inflammation control, and skin and hair models. The results are interesting, but results in animals do not directly predict results in people.

Human trials. Some clinical trials of stem cell-derived exosomes are under way abroad.
Standards. A JSRM guidance document on extracellular vesicles, published in April 2024, calls for evidence-based clinical use, safety first, and clear information for patients about risks and the level of evidence.
For skin and anti-aging uses specifically, there is not yet a well-designed, large human study that answers whether exosome treatment improves skin, hair or aging, by how much, or for how long.
What Japan's MHLW has said
In a notice dated 31 July 2024, addressed to the managers of regenerative medicine providers, the MHLW said that no drug using exosomes or other cell secretions from human stem cell culture fluid has been shown to be effective and safe and approved for marketing, either in Japan or abroad. The notice says that physicians who provide these treatments are responsible for taking particular care with safety, and it refers providers to the JSRM guidance.
The MHLW notice is a direction to providers, not a product approval. It does not state that exosome treatments are proven, and it does not state that they are unsafe. It says the evidence is not there yet and asks for care.
What the medical society has said
The JSRM issued a notice for patients on 27 December 2024 about exosomes derived from iPS cell culture fluid. It says that self-pay clinics have increasingly offered these treatments at high prices for anti-aging and other purposes, and that the clinical evidence for them has not been sufficiently established. It also says that the scientific basis for the expected effects has not been established. The notice recommends that patients ask their doctor for detailed information about evidence, safety and risks before deciding. It also notes that the 2024 annual meeting did not include clinical research results on iPS cell-derived exosomes.

Are exosome products regulated like stem cell treatments?
This is where readers often get confused. Japan's regenerative medicine Act covers treatments that use processed cells, and a clinic that offers a covered treatment must file a provision plan. The Act's Enforcement Regulations classify certain nucleic acid delivery treatments and exclude cell secretions from one category. The MHLW's 2024 notice, however, does not say that cell-free exosome products fall under the plan-filing system. Whether they should be brought under the Act is still under discussion in the research community.
In practice, this means a clinic offering an exosome treatment may not have a filed plan that you can compare with a stem cell treatment's plan. If a clinic says an exosome treatment is "registered" or "filed," ask exactly what was filed, under what law, and for which use.
What the evidence gap means in practice
The gap is not only about whether exosomes work. It is also about what is in a given product. Without a common quality standard, two products sold as exosome treatments can contain different vesicle populations, different proteins and different levels of contaminants, so a study of one product cannot be assumed to describe another. That is why both the MHLW's 2024 notice and the JSRM's 2024 notice put weight on the product's source, its quality and risk controls, and the evidence for the exact product being offered.
Risks and questions to ask
Exosome products are not living cells, but they are prepared from cell culture material, so contamination, impurities and the quality of the source cells can affect safety. Injection or intravenous infusion carries risks such as injection-site reactions and infection. Because there is no common quality standard, products differ widely.

Before you consider an exosome treatment, ask:
- Is the product exosomes or culture fluid? What cells was it made from, and whose cells?
- Who manufactures it, and what quality and infection testing has been done? Can you see the test reports?
- How is it given: topical, injection or intravenous infusion? What are the risks for that route?
- What human studies support the claimed effect, and how is the result measured?
- What does the price include, and how many treatments are planned?
If you are considering an exosome or stem cell treatment in Japan, send the clinic's name and the treatment name to our advisors. We will check whether the clinic has filed a provision plan for that treatment. For the framework, see how Japan regulates regenerative medicine.
Frequently asked questions
Is exosome therapy the same as stem cell therapy?
No. Exosomes are small vesicles released by cells and are not themselves cells. Stem cell therapy uses living cells. The two are regulated differently in Japan.
Does exosome therapy work for anti-aging or skin?
There is no reliable human evidence yet. The Japanese Society for Regenerative Medicine said in December 2024 that the clinical evidence for iPS cell-derived exosome treatment for anti-aging has not been established.
Has any exosome drug been approved?
According to the MHLW's notice of 31 July 2024, no exosome or culture-fluid product had been approved as a drug, either in Japan or abroad, at that time.
Does Japan's regenerative medicine Act cover exosome treatments?
The 2024 MHLW notice does not place cell-free exosome products under the plan-filing system, and the question of bringing them under the Act is still being discussed. Ask any clinic exactly which filing it relies on.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.
Sources: Ministry of Health, Labour and Welfare, Director for Research and Development Policy, Medical Affairs Bureau, notice on the use of stem cell culture fluid and exosomes (31 July 2024), which refers to the JSRM guidance on extracellular vesicles (April 2024) (mhlw.go.jp); Japanese Society for Regenerative Medicine, "Clinical application of iPS cell-derived exosomes" (caution notice, 27 December 2024) (jsrm.jp); Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) and Enforcement Regulations, e-Gov Law API. Checked November 2026; MHLW publications prevail.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.